We are on site at the Orange County Convention Center in Orlando, Florida, at the 2019 ASH Annual Meeting!
We have recapped some of the top news presented each day during the meeting, and later on we'll chat with Dr John Mascarenhas on new data in myeloproliferative neoplasms, and Dr Stephen Ansell on the latest updates in non-Hodgkin lymphoma.
Welcome to OncLive News Network! I'm Gina Columbus.
In multiple myeloma, results of the GRIFFIN trial showed that the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to have a significant improvement in response rates and depth of response, as well as stringent complete response and minimal residual disease negativity in patients with transplant-eligible, newly diagnosed disease.
The safety profile was also found to be consistent with prior results of this regimen, and investigators noted that the ongoing study has patients continuing on maintenance therapy.
Also in multiple myeloma, updated results of the phase III ALCYONE trial showed that the addition of daratumumab to bortezomib, melphalan, and prednisone, known as VMP, prolonged overall survival compared with VMP alone in patients with transplant-ineligible newly diagnosed disease.
The quadruplet regimen continued to show an improvement in progression-free survival, which was maintained during the subsequent line of therapy.
Interim phase II results showed that enasidenib and azacitidine led to significantly improved complete remission and overall response rates in newly diagnosed patients with acute myeloid leukemia who harbor IDH2 mutations.
Additionally, the combination led to significant mutant IDH2 VAF reductions versus azacitidine alone, and it was linked with a tolerable safety profile.
The CD123-targeting antibody-drug conjugate IMGN632 demonstrated a manageable safety profile and broad therapeutic window in high risk patients with relapsed/refractory AML and blastic plasmacytoid dendritic cell neoplasm. Due to these data and preclinical findings, the ADC will now be explored as monotherapy in patients with relapsed/refractory BPDCN and MRD—positive AML.
Combination therapy with navitoclax and ruxolitinib was found to be well tolerated in patients with primary or secondary myelofibrosis who previously received ruxolitinib.
The regimen demonstrated clinically meaningful spleen responses, allelic burden reductions, total symptom score improvements, and encouraging improvements in bone marrow fibrosis.
Also in myelofibrosis, an analysis showed that select patients on the JAKARTA or JAKARTA2 trials achieved similar spleen volume and symptom response rates with fedratinib, whether the JAK2 inhibitor was used in patients who previously received ruxolitinib or were naïve to the agent.
The findings suggest that fedratinib is a promising new treatment option for patients with myelofibrosis and low platelet counts.
In mantle cell lymphoma, long-awaited results of the phase II ZUMA-2 trial showed that that treatment with the CAR T cell therapy KTE-X19 led to significant and durable benefit in patients with relapsed/refractory MCL. With at least 1 year of follow-up, results also showed that the treatment led to a majority of patients achieving a complete response. It also had a manageable safety profile.
That's all for today. For more coverage of the 2019 ASH Annual Meeting, visit www.OncLive.com.
Thank you for watching OncLive News Network! Signing off from Orlando, Florida, I'm Gina Columbus.